Theorem Clinical Research Expands Leadership and Prepares for Growth
News Nov 13, 2014
Theorem Clinical Research has named Kathryn Bohannon as vice president of biopharmaceutical development and Angela Weston as vice president of business development in Europe and Asia.
Bohannon increases Theorem’s scientific and medical leadership in pediatrics and rare disease with almost 20 years of diverse pharmaceutical research and development experience, including Phase I-IV clinical research, laboratory research and development as well as U.S. and global project management and direct sales and marketing.
She has developed and managed projects across multiple therapeutic areas and clinical settings, including the Best Pharmaceuticals for Children Act - Data Coordinating Center within the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Weston brings more than 20 years of experience to Theorem, spanning a broad range of commercial disciplines in the pharmaceutical, biotech and medical device industries. She has worked extensively in business development, previously serving as senior vice president for business development at a global clinical contract research organization.
In this role, she organized and managed the pharmaceutical, medical device and clinical resource sales teams. Additionally, Weston is a clinical nurse specialist and paramedic.
“These professionals further enhance our capabilities and client services,” said John Potthoff, Theorem president and CEO. “We have the right experts in place to provide meaningful expertise in key aspects of clinical trials.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE